Amryt METRE
Brief description of study
This is a 12-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the safety and efficacy of daily subcutaneous metreleptin treatment in subjects with Familial Partial Lipodystrophy (FPLD). Subjects will be assigned to 1 of 3 groups depending on HbA1c and fasting TGs levels. Participants will complete 10 visits over a 12 month treatment phase followed by 2 safety follow-up visits at 1 month and 3 months post-treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
